H

PTO/SB/05 (03-01)

1gh 10/31/2002. OMB 0651-0032

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR

Attorney Docket No.		LEX-0208-USA					
First Inventor		Walke et al.					
Title	Novel Human Ion C	ovel Human Ion Channel Proteins and Polynucleotides Encoding					
Everage Mail Lahol No.		El 903203040 HC					

6	1.53 (b))	under er er r	Expre	ess Mail Label I	Vo.	EL 89339	3919 US		
	PLICATION ELEMEI er 600 concerning utility		DDRESS TO	' : в	ssistant Comr ox Patent App /ashington, D				
1 Fee Trans (Submit an orig 2 X Applicant of See 37 CF 3 X Specificati (preferred arre - Descriptive - Cross Refer - Statement F - Reference to or a comput - Background - Brief Summ - Brief Descriptive - Claim(s) - Abstract of t 4 Drawing(s) Sheets 5 Oath or Declaration a X Unexect b. Copy fr	mittal Form (e.g., PTO mal and a duplicate for fee procession and a duplicate for fee program for the Invention and the Invention arry of the Invention array of the Invention	/SB/17) /SB/17	9 10. 11 12. 13.	8 Nucleotide and/(if applicable, at a	ROM of Courter I or Amir I necession Diagram Arrans ion Diagram Arrans Areceiches Spirit I or Amir I or Am	/ashington, Dor CD-R in or Program (Ano Acid Sequence Ano Acid Sequence List diskette; or paper ent verifying APING AF Papers (cov. b) Statemes an assignation Document of Postcard ecifically ite	C 20231 duplicate, large tab (appendix) ence Submission ble Form (CRF) ing on: g identity of above PPLICATION PARTICLE er sheet & document mt	copies ARTS ent(s)) ver of executed	
i. DELETION OF INVENTOR(S) signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1 63(d)(2) and 1.33(b).				Certified Copy of Priority Document(s) (if foreign priority is claimed) Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent					
Application Data Sheet See 37 CFR 1.76 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No. / Prior application information: Examiner Group Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS									
X Customer Number or Bar Code Label (Insert Customer No.)				or Correspondence address below					
Name	Lance K. Ishimoto	PATEN	T TRADEMA	RK OFFICE					
Address	4000 Research Forest Drive								
City	The Woodlands	State	TX		T	Zin	77201		
Country	USA	Telephon	281-863-3	333	_	Zip Fax	77381		
Name (Print/Type) Lance K. Ishimoto Registration No. (Attorney/Agent) 41866									
Signature	Xack Shite		7 4	eg UD 40162		- Date	July 30, 2001		

tree from the first tree f

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Walke et al.

U.S. Ser. No.:

To Be Assigned

Attorney Docket No.: LEX-0208-USA

Filing Date:

July 30, 2001

For:

Novel Human Ion Channel Proteins and Polynucleotides Encoding the

Same

VERIFIED STATEMENT

Asst. Commission for Patents Washington, D.C. 20231

Sir:

- I, DRENDA D. THOMAS, do declare and state as follows:
- 1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. Sec. 1.821-1.825 in connection with the above-captioned patent application.
- 2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed,

July 30, 2001

Date

Drenda D. Thomas